to determine the effects of Ramadhan fasting on GERD symptoms.
a total of 130 GERD patients participated in this study. Patients were divided into two groups, i.e. those who performed Ramadhan ...fasting (n=66), and those who did not perform Ramadhan fasting (n=64). The evaluation was done using Indonesian version of GERD questionnaire (GERD-Q) between the two groups, and between Ramadhan month and non-Ramadhan month in the Ramadhan fasting group.
there was a statistically significant difference (p<0.01) in the median of GERD-Q score in Ramadhan-fasting group subjects and non-Ramadhan-fasting group subjects (0 vs. 4). Moreover, a statistically significant difference (p<0.01) was also found in the median of GERD-Q score in Ramadhan-fasting group subjects and non-fasting group subjects (p<0.01).
subjects in Ramadhan fasting group, GERD symptoms experienced less severe during fasting month (Ramadhan) than non-fasting month. During Ramadhan month, GERD symptoms were also milder in Ramadhan fasting group than those in non-fasting group subjects.
Helicobacter pylori infection is commonly found worldwide. In Indonesia, the prevalence of H. pylori infection is 22.1%. The bacteria are responsible for gastritis, peptic ulcer disease (PUD), and ...gastric cancer.Helicobacter pylori may also has a role in functional dyspepsia. Diagnostic approach consists of noninvasive and invasive examinations. One of the invasive strategy is upper gastrointestinal (UGI) endoscopy and gastric mucosa biopsy.
to investigate the side effects and survival of endoscopic variceal ligation by using Indonesian Endoscopic Ligator versus Endoscopic Variceal Sclerotherapy.
we studied the medical records and ...endoscopy reports of patients who underwent endoscopic variceal ligation (EVL) or endoscopic sclerotherapy (EST) from January 2003 until December 2006. EST was done using ethoxysclerol injection; and ligation was done using a home-made Indonesian endoscopic ligating device. Patient characteristics, side effects of EVL and EST, as well as survival and length of stay were collected. Data of side effects was analyzed by chi-square test.
there were no statistically significant differences of patients characteristics among both groups. The side effects in EVL group (29.2%) were less frequent than the EST group (60.9%) (p = 0.009). The death side effect in the EVL group (1.0%) was less frequent than in the EST group (21.7%) (p<0.001). The four-year survival in patients who had EVL and EST were 91.7% and 16.7%, respectively (p<0.001).
EVL had fewer side effects than EST in the treatment of esophageal varices bleeding. Death in the EVL group was lower than in the EST group.
to obtain the proportion of dyspepsia symptom in non-ulcerative dyspepsia patient after eradication treatment of H. pylori, and recent status of H. pylori after eradication therapy.
cross-sectional ...study in patients with history symptoms of dyspepsia in non ulcer dyspepsia with positive H. pylori and had been administered eradication treatment of H. pylori for 1 week in 2002-2007 period. Conditions that influence the result of urea breath test such as proton pump inhibitor, antibiotic treatment, and gastric malignancy have been excluded. Patients were invited to be interviewed about current symptoms of dyspepsia and then underwent urea breath test (UBT) examination to identify H. pylori. Global overall symptom of dyspepsia scale was used to assess the symptoms of dyspepsia.
twenty one patients (14 male and 11 female) fulfilled the eligibility criteria for this study, 9 patients with eradication treatment history less than 1 year, and 12 patients more than 1 year. The symptoms of dyspepsia were evaluated and as many as 17 patients (81%) dyspepsia symptoms' were subsided and 4 patients had persistent symptoms after eradication. After eradication treatment, 17 patients (81%) resulted with negative Helicobacter pylori findings, and 4 patients remained positive. One patient of the positive group was reinfected by H. pylori, proved by previous negative result of UBT. In the negative group, 13 patients (76.4%) dyspepsia symptoms' were free from dyspepsia symptoms, and 4 patients had persistent symptoms. All the symptoms of the patients in the positive group were relieved.
majority of patients had improvement of dyspepsia symptoms after eradication treatment, and 81% of patients had negative H. pylori findings, proved by UBT after eradication. The percentage of symptomatic improvement on H. pylori negative patients after eradication is 76.4%.
Background/Aims
Gastroparesis is identified as a subject that is understudied in Asia. The scientific committee of the Asian Neurogastroenterology and Motility Association performed a Knowledge, ...Attitude, and Practices survey on gastroparesis among doctors in Asia.
Methods
The questionnaire was created and developed through a literature review of current gastroparesis works of literature by the scientific committee of Asian Neurogastroenterology and Motility Association.
Results
A total of 490 doctors from across Asia (including Bangladesh, China, Hong Kong, Indonesia, Japan, Malaysia, Myanmar, the Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam) participated in the survey. Gastroparesis is a significant gastrointestinal condition. However, a substantial proportion of respondents was unable to give the correct definition and accurate diagnostic test. The main reason for lack of interest in diagnosing gastroparesis was “the lack of reliable diagnostic tests” (46.8%) or “a lack of effective treatment” (41.5%). Only 41.7% of respondents had access to gastric emptying scintigraphy. Most doctors had never diagnosed gastroparesis at all (25.2%) or diagnosed fewer than 5 patients a year (52.1%).
Conclusions
Gastroparesis can be challenging to diagnose due to the lack of instrument, standardized method, and paucity of research data on normative value, risk factors, and treatment studies in Asian patients. Future strategies should concentrate on how to disseminate the latest knowledge of gastroparesis in Asia. In particular, there is an urgent need to estimate the magnitude of the problems in high risk and idiopathic patients as well as a standardized diagnostic procedure in Asia.
(J Neurogastroenterol Motil 2021;27:46-54)
Background/Aims
There has been major progress in our understanding of the irritable bowel syndrome (IBS), and novel treatment classes have emerged. The Rome IV guidelines were published in 2016 and ...together with the growing body of Asian data on IBS, we felt it is timely to update the Asian IBS Consensus.
Methods
Key opinion leaders from Asian countries were organized into 4 teams to review 4 themes: symptoms and epidemiology, pathophysiology, diagnosis and investigations, and lifestyle modifications and treatments. The consensus development process was carried out by using a modified Delphi method.
Results
Thirty-seven statements were developed. Asian data substantiate the current global viewpoint that IBS is a disorder of gut-brain interaction. Socio-cultural and environmental factors in Asia appear to influence the greater overlap between IBS and upper gastrointestinal symptoms. New classes of treatments comprising low fermentable oligo-, di-, monosacharides, and polyols diet, probiotics, non-absorbable antibiotics, and secretagogues have good evidence base for their efficacy.
Conclusions
Our consensus is that all patients with functional gastrointestinal disorders should be evaluated comprehensively with a view to holistic management. Physicians should be encouraged to take a positive attitude to the treatment outcomes for IBS patients.
(J Neurogastroenterol Motil 2019;25:343-362)
PDF
